Contrasting Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Interpace Biosciences (OTCMKTS:IDXG)

Insider and Institutional Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 5.7% of Interpace Biosciences shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Comparatively, 5.5% of Interpace Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Health Sciences Acquisitions Co. 2 and Interpace Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Interpace Biosciences	63.46%	493.02%	137.46%

Risk & Volatility

Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Comparatively, Interpace Biosciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Earnings and Valuation

This table compares Health Sciences Acquisitions Co. 2 and Interpace Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A
Interpace Biosciences	$38.73 million	0.22	$24.58 million	($0.02)	-96.70

Interpace Biosciences has higher revenue and earnings than Health Sciences Acquisitions Co. 2.

Summary

Interpace Biosciences beats Health Sciences Acquisitions Co. 2 on 6 of the 8 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.